Intersect ENT Inc (NASDAQ:XENT) – Equities researchers at Svb Leerink issued their Q1 2020 earnings per share estimates for shares of Intersect ENT in a report released on Tuesday, May 7th. Svb Leerink analyst R. Newitter forecasts that the medical equipment provider will post earnings of ($0.08) per share for the quarter. Svb Leerink currently has a “Market Perform” rating and a $29.00 target price on the stock. Svb Leerink also issued estimates for Intersect ENT’s Q2 2020 earnings at ($0.10) EPS, Q3 2020 earnings at ($0.09) EPS and Q4 2020 earnings at ($0.06) EPS.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Monday, May 6th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.05). The company had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $26.34 million. Intersect ENT had a negative net margin of 21.13% and a negative return on equity of 19.04%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.21) earnings per share.
Several other research firms also recently commented on XENT. BidaskClub downgraded Intersect ENT from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Leerink Swann downgraded Intersect ENT from an “outperform” rating to a “market perform” rating and set a $25.75 price objective for the company. in a research note on Tuesday. ValuEngine downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Zacks Investment Research downgraded Intersect ENT from a “hold” rating to a “strong sell” rating in a research note on Friday, May 3rd. Finally, Canaccord Genuity upped their price objective on Intersect ENT from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $30.96.
XENT opened at $26.26 on Wednesday. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -34.55 and a beta of 0.62. Intersect ENT has a 52 week low of $24.39 and a 52 week high of $42.95.
Several hedge funds have recently modified their holdings of XENT. BlackRock Inc. raised its stake in shares of Intersect ENT by 12.9% during the 3rd quarter. BlackRock Inc. now owns 2,607,083 shares of the medical equipment provider’s stock worth $74,954,000 after buying an additional 296,973 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Intersect ENT by 44.6% during the 4th quarter. Westfield Capital Management Co. LP now owns 685,856 shares of the medical equipment provider’s stock worth $19,327,000 after buying an additional 211,574 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Intersect ENT during the 4th quarter worth approximately $3,697,000. Morgan Stanley raised its stake in shares of Intersect ENT by 126.1% during the 3rd quarter. Morgan Stanley now owns 234,650 shares of the medical equipment provider’s stock worth $6,747,000 after buying an additional 130,847 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in shares of Intersect ENT during the 4th quarter worth approximately $3,382,000. 95.98% of the stock is owned by institutional investors and hedge funds.
In other news, insider Lisa D. Earnhardt sold 29,588 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $28.43, for a total transaction of $841,186.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jeryl L. Hilleman sold 30,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $32.07, for a total value of $962,100.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 106,246 shares of company stock valued at $3,269,037. 5.90% of the stock is owned by company insiders.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Further Reading: What is range trading?